Abstract: A nanodevice includes an array of metal nanorods formed on a substrate. An electropolymerized electrical conductor is formed over tops of a portion of the nanorods to form a reservoir between the electropolymerized conductor and the substrate. The electropolymerized conductor includes pores that open or close responsively to electrical signals applied to the nanorods. A cell loading region is disposed in proximity of the reservoir, and the cell loading region is configured to receive stem cells. A neurotrophic dispensing material is loaded in the reservoir to be dispersed in accordance with open pores to affect growth of the stem cells when in vivo.

Abstract: The present invention relates to a pharmaceutical composition containing rifaximin in the form of two different polymorphs as well as a method of preparing the same.

Abstract: The present invention concerns a composition, in particular in the form of aqueous dispersion for caring for and/or making up keratin materials comprising, in a physiologically acceptable medium, a) one aqueous phase; and b) at least microcapsules comprising:—an inner core comprising at least a dispersion of at least one reflective agent, in particular bismuth oxychloride, in at least one oil, and—at least one outer shell formed of a wall-forming polymeric material surrounding the said core, the said outer shell comprising i) at least one wall-forming polymer, and ii) optionally at least one plasticizer and/or at least one opaque substance and/or at least one fatty acid salt. The present invention concerns also a cosmetic process for caring for and/or making up keratinic materials, comprising application on said keratinic materials in particular on the skin of a composition as above defined.

Abstract: The present invention provides a core-shell structure having high skin permeability. The core-shell structure includes a core portion containing a hydrophilic drug having a molecular weight of 400 or more; and a shell portion containing a surfactant, and the core portion is a solid, the hydrophilic drug has a water-octanol partition coefficient of ?3 or more and 6 or less, the surfactant has an alkyl group or an alkenyl group having 10 to 20 carbon atoms, and a mass ratio between the hydrophilic drug and the surfactant (hydrophilic drug:surfactant) is 1:5 to 1:20.

Abstract: One embodiment of the present disclosure provides a method for producing an angle-independent colloidal particles-based structure, the method having: preparing two or more types of hollow colloidal particles, wherein the types are distinguished based on a size of the hollow colloidal particles thereof, wherein the types have different particle sizes; and dispersing the at least two types of hollow colloidal particles to produce an amorphous structure, wherein the amorphous structure realizes the same color independently of an angle of an incident light thereto.

Abstract: A method for preparing solid materials is described. One aspect of the method includes the steps of providing a mixture comprising an organic material in a blend of a solvent and non-solvent for the organic material, distributing the mixture into either droplets or granules, and evaporating the solvent and non-solvent mixture to form particles having an average size of from about 0.5 ?m to about 5000 ?m.

Abstract: A solid cosmetic composition includes (i) a natural colourant, (ii) starch, and (iii) mica.

Abstract: A method of preparing an orally ingestible hard boiled product, comprising: i) heating a sugar material to a first temperature sufficient to liquefy the sugar material; ii) cooling the liquefied sugar material to provide a cooled sugar material having a solid or semi-solid form; iii) heating the cooled sugar material to a second temperature, which is lower than the first temperature; iv) combining the sugar material with one or more temperature sensitive ingredients before, during, or after said heating step iii), but after said cooling step ii), such that an intimate mixture of the second liquefied sugar material and the one or more temperature sensitive ingredients is provided; and v) cooling the intimate mixture to form an orally ingestible product. Orally ingestible hard boiled products prepared according to this method are also provided.

Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.

Abstract: The invention describes novel compositions and methods utilized for treating disorders and/or conditions associated with the epidermal and/or dermal level of the skin. Such disorders include hyperhidrosis, bromhidrosis, and chromhidrosis, One representative composition of the invention comprises; water, alcohol, aluminum sesquichlorohydrate, hydroxypropyl methyl cellulose, polysorbate 20, isopropyl myristate, eucalyptus oil, silicone oil, alkyl benzoate, glycerine, talc, a hydrophillic silica, a hydrophobic silica, phenoxyethanol and ethylhexyl glycerine.

Abstract: Provided are methods for determining the amount of lacosamide in a sample using mass spectrometry. The methods generally involve ionizing lacosamide in a sample and detecting and quantifying the amount of the ion to determine the amount of lacosamide in the sample.

Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.

Abstract: The present invention provides Glatiramer acetate compositions in a non-gelling matrix, formulated for sublingual delivery.

Abstract: Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.

Abstract: Methylnaltrexone nasal formulations are discloses which provide improved bioavailability over oral dosage forms and improved patient compliance over injectable dosage forms. Also disclosed are methods of making the nasal formulations and methods of using, specifically to treat the side effects of opioid drug use, such as constipation, and other indications.

Abstract: The present disclosure relates generally to rapid-release pharmaceutical dosage unit tablets containing a drug that is an inhibitor of the mitogen-activated protein kinase enzyme, a filler and a disintegrant, and to processes for forming the tablets. More specifically, the present disclosure relates to pharmaceutical dosage unit tablets containing cobimetinib, a least one filler, at least one lubricant and at least one disintegrant, and to methods for preparing the tablets from granules formed by dry granulation.

Abstract: Disclosed is a method of manufacturing a dishwasher including: forming a first layer containing zirconium oxide and silicon oxide on a surface of the inner wall at a heat treatment of 200° C. or higher; forming a second layer containing an oxoacid on a surface of the first layer at a heat treatment temperature lower than the heat treatment temperature of the first layer; and obtaining a thin-film layer containing zirconium oxide and silicon oxide on the surface of the inner wall and having a contact angle of water of 20° or less on the surface, after removing the second layer by using a washing method, in which the first layer contains the zirconium oxide in an amount of 80 mass % or more in terms of oxide and the silicon oxide in an amount of 1-20 mass % in terms of oxide.

Abstract: The described invention provides a compound comprising an organometallic complex comprising a core of ruthenium and sphingomyelin, with the option of added zinc, that, in a therapeutic amount, through further connections with contributing organic ligands, are effective as chemotherapeutic agents that have an anti-tumor or anti-cancer effect on a tumor comprising tumor cells including a cytotoxic effect on of the tumor cells, inhibition of the growth of the tumor comprising the tumor cells, inhibition of migration of the tumor cells, or any combination of these effects.

Abstract: Processes of intraoperative diagnosis and elimination of tumors or micro-tumors or cancer cells or tumor micro-environment (TME) with plasmonic nanobubbles (PNBs) are disclosed. The diagnosis and surgical processes disclosed can improve standard onco-surgery through one or more of the following: real-time intraoperative local detection of MRD in vivo with high cancer sensitivity and specificity; real-time guidance of surgery to precisely eliminate resectable MRD with minimal morbidity by resecting only PNB-positive volume instead of a larger volume; intraoperative selective elimination of unresectable MRD through the mechanical impact of lethal cancer cell-specific PNBs without damaging adjacent normal cells and tissues; and prediction of the surgical outcome through the metrics of PNB signals.

Abstract: The current invention involves the surprising finding that when carboxylated particles, such as carboxylated polystyrene, PLGA, or diamond particles are administered to subjects, inflammatory immune responses are ameliorated. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same carboxylated particles.

Abstract: Disclosed embodiments enable apparatus and methodologies that are provided for three-dimensional construction of tissues in the body at locations internal to the body.

Abstract: Polymers including poly(amine-co-ester), poly(amine-co-amide), or a combination thereof, and nanoparticles, particularly solid core nanoparticles, formed therefrom are provided. Solid core nanoparticles fabricated from hydrophobic polymers often require the presence of cationic complexing agents to stabilize negatively charged active agents such as siRNA. However, complexing agents are optional in the disclosed formulations because the nanoparticles contain cationic amines to stabilize negatively charged nucleic acids and hydrophobic domains to condense the nucleic acid into the core of the formed nanoparticles, thus improving encapsulation efficiency. This increase in nucleic acid loading allows the disclosed solid core nanoparticles to deliver more nucleic acid per cell without increasing total polymer delivered, further reducing cytotoxicity.

Abstract: Compositions and methods of making and using of microparticle compositions that provide faster flow or improved injectability through smaller or small-diameter needles have been developed. Notably, the microparticle compositions can be successfully delivered or administered through smaller-diameter needles than other microparticle compositions prepared from biocompatible or biodegradable polymers including, for example, poly(lactide), poly(lactide-co-glycolide), polycaprolactone, or poly-3-hydroxybutyrate. The microparticle compositions can exhibit a higher solids loading for a given needle size and/or faster flow through needles than other microparticle compositions. Further, blending or mixing the polymer of the microparticle composition with other polymer formulations can enhance the injectability of the resulting formulation.

Abstract: The present invention relates to pyrrolidone carboxylic acid (PCA) and/or pharmaceutically acceptable salts or derivatives thereof for use in the treatment of ocular diseases and/or disorders. A further object of the present invention are compositions comprising pyrrolidone carboxylic acid (PCA) and/or pharmaceutically acceptable salts or derivatives thereof, at least one physiologically acceptable excipient, and optionally at least one additional active ingredient for use in the treatment of ocular diseases and/or disorders.

Abstract: The present invention relates to a new pharmaceutical composition containing nicotinic acid, nicotinamide, tryptophanor related compounds for positively influencing the intestinal microbiota. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.

Abstract: A solid dosage form comprises coated particles of bisphosphonate or a pharmaceutically acceptable analog or derivative thereof.

Abstract: A template-free method of preparing zeolites from biomass can include using rice husk ash waste material as a precursor material. The zeolites can include ZSM-5 zeolites, such as, hierarchical pure zeolites and metal-loaded (Cu, Ni) ZSM-5 zeolites. This method allows for production of zeolites in a low cost and environmentally friendly manner. These ZSM-5 zeolites may be used for numerous applications, including killing cancer cells. The cancer cells may be human lung cancer cells.

Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) at least two distinct biocompatible nanoparticles and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the at least two distinct biocompatible nanoparticles potentiate the compound(s) of interest efficiency. The at least two biocompatible nanoparticles can be administered sequentially or simultaneously to the subject but are to be administered separately, typically with an interval of between more than about 5 minutes and about 72 hours, from the at least one compound of interest, preferably before the administration of the at least one compound of interest, to said subject. The longest dimension of the at least two biocompatible nanoparticles is typically between about 4 nm and about 500 nm.

Abstract: A pharmaceutical composition comprises multiparticulates comprising a melt-congeal core and a solid amorphous dispersion layer of a poorly water soluble drug and polymer. The multiparticulates are suitable for improving bioavailability of poorly water soluble drugs. The melt-congeal cores facilitate application of the solid amorphous dispersion layer, and allow incorporation of additional optional components to the core so as to adjust the release of drug from the multiparticulate.

Abstract: Calcitonin analogues as a medicament for producing a decrease in liver triglycerides or for reducing fat accumulation in the liver of a subject are provided.

Abstract: The invention provides therapeutic magnetic nanoparticles containing a therapeutic agent connected to a magnetic nanoparticle core through a stable functional group and a linker that can be induced to release the therapeutic agent from the core, through hydrolysis of the functional group. Also provided are methods for making nanoparticles, and methods for using nanoparticles.

Abstract: Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV).

Abstract: The present invention generally relates to bioactive composites of polymer and glass and, more particularly, to bioactive implants. The present invention also relates to methods of manufacturing bioactive composites. The bioactive composite finds utility in a variety of load-bearing clinical applications including spine, orthopaedic and dental procedures.

Abstract: A non-covalently assembled hydrogel or organo-gel composition with serum stability is described. Low molecular weight (<2,500 Da), generally regarded as safe (GRAS), materials assemble in the presence of a stabilizing agent at an appropriate molar percentage, forming hydrogel or organo-gel with nanostructures that resist disassembly or destabilization in serum for an extended period of time. The composition is used to deliver one or more therapeutic, prophylactic, or diagnostic agents, allowing for controlled release in response to biological stimuli such as enzymes and a greatly improved dosing efficacy.

Abstract: The present invention relates to non-viral gene therapy methods and compositions for treatment of hyperproliferative disease in humans. More specifically, the invention is directed, in one embodiment, to lipid formulations which form stable liposome structures, capable of efficient in vivo nucleic acid transfer. In other embodiments, methods and compositions are directed to liposome transfer of anti-proliferative nucleic acids, wherein the transfer of the nucleic acids is cell specific via cell specific targeting moieties. The present invention, thus provides non-viral, liposome compositions and methods of gene transfer particularly useful for targeting and treating hyperproliferative disease.

Abstract: A personal care composition includes an ozone-stressed yeast lysate; and a preservative, in which the preservative is selected from phenoxyethanol, isopropyl alcohol, benzyl alcohol, propylene glycol, butylene glycol, pentylene glycol, methylparaben, propylparaben, butylparaben, benzalkonium chloride, Quaternium 15, methylisothiazolinone, methylchloroisothiazolinone, DMDM hydantoin, imidazolidinyl urea, diazolidinyl urea, butylated hydroxytoluene, tocopherol, triclosan, chlorohexidine digluconate, and combinations thereof, and the ozone-stressed yeast lysate is produced by a method including exposing growing yeast to ozone by aerating the yeast for a time period of between five minutes and seventy-two hours with an aeration gas having an ozone concentration of from 0.0001 millimolar (mM) to 1.

Abstract: Systems and methods for coating a particle core with a layer-by-layer film are disclosed.

Abstract: Provided are pharmaceutical compositions and methods of treating or preventing edema, using an anti-T cell agent, an anti-TGF-?1 agent, or an anti-angiotensin agent, preferably a combination of at least two such agents. The pharmaceutical compositions can be formulated for systemic or local administration, and are preferably administered topically.

Abstract: Disclosed herein are generally to methods and systems that facilitate imaging of cells on a substrate and more particularly to pre-implantation (in vitro) and post-implantation (in vivo) imaging of cell-seeded substrates implanted in target tissues in the context of stem cell therapy.

Abstract: Methods, systems, and devices are disclosed for fabricating and implementing nanoscale and microscale structured carriers to provide guided, targeted, and on-demand delivery of molecules and biochemical substances for a variety of applications including diagnosis and/or treatment (theranostics) of diseases in humans and animals. In some aspects, a nanostructure carrier can be synthesized in the form of a nanobowl, which may include an actuatable capping particle that can be opened (and in some implementations, closed) on demand. In some aspects, a nanostructure carrier can be synthesized in the form of a hollow porous nanoparticle with a functionalized interior and/or exterior to attach payload substances and substances for magnetically guided delivery and controlled release of substance payloads.

Abstract: A method of making natural polymer (nano)particles, comprises two immiscible phases and a surface active agent, wherein one phase includes a natural polymer source and ionic liquid; stirring the combined phases with surfactant to form a microemulsion; adjusting the ratios of ionic liquid, surfactant, and immiscible phase to determine a particular size of natural polymer nanoparticles; stirring antisolvent into the emulsion; diluting the emulsion; and washing and drying precipitated polymer (nano)particles from the emulsion. The immiscible phase comprises at least one of immiscible solvent, oil, or immiscible ionic liquid. The ionic liquid phase includes natural polymer dissolved in ionic solvent. The antisolvent is water, other protic solvent or additive. The emulsion is diluted with, more immiscible phase, 1-butanol, or a mutually miscible solvent, or oil. The emulsion is diluted with an excess of the volume of the emulsion.

Abstract: The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acute coronary syndrome such as unstable angina and acute myocardial infarction.

Abstract: The disclosure relates to metal nanoparticle compositions and their methods of formation and use, in particular gold nanoparticles (AuNP) and gold-coated magnetic nanoparticles. Compositions according to the disclosure include aqueous suspensions of metal nanoparticles that are stabilized with one or more carbohydrate capping agents and/or that are functionalized with one or more binding pair members for capture/detection of a target analyte. The nanoparticle suspensions are stable for extended periods and can be functionalized as desired at a later point in time, typically prior to use in an assay for the detection of a target biological analyte. The stable nanoparticle suspension can be formed by the aqueous reduction of oxidized metal precursors at non-acidic pH values in the presence of a carbohydrate-based capping agent such as dextrin or other oligosaccharides.

Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.

Abstract: One aspect of the present invention relates to a multicomponent and biocompatible nanocomposite material, including a graphene structure formed with a plurality of graphene layers; and gold/hydroxyapatite (Au/HA) nanoparticles distributed within the graphene structure; where the nanocomposite material is formed by heating an Au/HA catalyst thin film with a carbon source gas to perform radio frequency chemical vapor deposition (RF-CVD).

Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.

Abstract: A stable dry powder composition for inhalation includes acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) in a range of about 1 ?m to about 5 ?m. The dry powder composition may contain a pharmaceutically acceptable excipient, such as a stearate, in an amount ranging from about 0.04% (w/w) to about 0.06% (w/w), or from about 0.4% (w/w) to about 0.6% (w/w), of the composition.

Abstract: The present disclosure described methods, systems, and techniques for applying contrast-enhanced ultrasound to locate areas of blockage within retinal vessels and to break up clots that are causing damage. In addition to identifying the damaged area, the researchers anticipate that the initial image may serve as a baseline for monitoring the effect of treatment on the vessel, which may be achieved in multiple ways. The vibration effect of the ultrasound itself may suffice to dislodge clots. The microbubbles may also be coated or filled with medication, with ultrasonic shock waves activating the coating or causing mini explosions to release the medicine. Loading the microbubbles with a therapeutic agent, visualizing their presence at the diseased site using the ultrasound diagnostic mode, and then activating the microbubbles to release their contents at the targeted lesion could be a powerful and effective way to reverse occlusion without harming other areas of the eye or body.

Abstract: Various embodiments are described herein for a device and method for an ingestible medical device with a rotatable element. In some described embodiments, the ingestible medical device includes a storage sub-unit with multiple chambers each having an opening for collecting or dispensing substances from the GI tract. The device further comprises a chamber enclosure with an access port. One of the chamber enclosure and the storage sub-unit are rotatable to allow for aligning the access port with a chamber opening. The ingestible medical device includes a sensor for positioning the access port of the chamber enclosure or the storage sub-unit as one of these elements rotates.

Abstract: The present invention relates to a pharmaceutical composition comprising Levetiracetam, Brivaracetam or Seletracetam as active ingredient, the invention relates specifically to a prolonged release formulation.